Shares of Relypsa Inc. (NASDAQ:RLYP) traded up 58.4% during trading on Thursday . The stock traded as high as $31.94 and last traded at $31.84, with a volume of 31,790,319 shares trading hands. The stock had previously closed at $20.10.

Several analysts recently commented on the company. Brean Capital reaffirmed a “buy” rating and issued a $26.00 price target on shares of Relypsa in a research note on Sunday, April 17th. Mizuho reaffirmed a “hold” rating on shares of Relypsa in a research note on Sunday, April 17th. BTIG Research reaffirmed a “buy” rating and issued a $45.00 price target on shares of Relypsa in a research note on Saturday, April 9th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of Relypsa in a research note on Saturday, April 9th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $42.00 price target on shares of Relypsa in a research note on Wednesday, May 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $35.03.

The firm has a 50 day moving average price of $19.03 and a 200-day moving average price of $17.53. The stock’s market capitalization is $1.43 billion.

Relypsa (NASDAQ:RLYP) last announced its earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.46) by $0.20. The firm had revenue of $12.40 million for the quarter, compared to the consensus estimate of $6.88 million. During the same quarter last year, the business posted ($0.78) EPS. Analysts forecast that Relypsa Inc. will post ($5.95) EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC raised its position in shares of Relypsa by 9.9% in the fourth quarter. ProShare Advisors LLC now owns 38,272 shares of the company’s stock worth $1,085,000 after buying an additional 3,445 shares during the period. Nationwide Fund Advisors raised its position in shares of Relypsa by 0.6% in the fourth quarter. Nationwide Fund Advisors now owns 42,287 shares of the company’s stock worth $1,198,000 after buying an additional 272 shares during the period. California State Teachers Retirement System raised its position in shares of Relypsa by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 60,422 shares of the company’s stock worth $1,712,000 after buying an additional 1,084 shares during the period. Ashburton Jersey Ltd purchased a new position in shares of Relypsa during the fourth quarter worth $1,725,000. Finally, California Public Employees Retirement System purchased a new position in shares of Relypsa during the fourth quarter worth $3,826,000.

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.